Many people ask: “what causes cancer”? Is it geneti...
The Benefits of Choosing Fresh Patient Ex Vivo Tumor Organoids.
Mar 03, 2020
According to a recent JAMA Study (1) examining the R&D process for 10 FDA-approved cancer drugs, the companies surveyed spent a median of 648 million dollars and a median of 7.3 years to develop an individual cancer drug. Even with hundreds of millions of dollars and years spent on R&D, many drugs validated in lab tests still fail to show therapeutic efficacy. For example, a recent study (2) of 640 novel therapeutics found that cancer drugs only had a 27% chance of receiving approval by the FDA. This failure in the clinical trial phase often occurs because in order to assess the efficacy of their agents, cancer drug developers frequently use in vivo and in vitro tumor models that fail to recapitulate the complexity of the patient tumor microenvironment.
We believe our tumor organoid models, using fresh patient tumor samples, are the most clinically relevant drug testing platforms to assess the therapeutic efficacy of immuno-oncology agents in ex vivo studies. Nilogen’s tumor organoids maintain an unaltered tumor immune microenvironment that is very similar to conditions found in a patient’s tumor. These similar conditions allow scientists to observe how immuno-oncology agents interact with the tumor immune microenvironment, gain a better understanding of the mechanism of action and evaluate drug efficacy.
Nilogen’s extensive procurement network and its proprietary method for preparing the tumor organoids provide scientists with a convenient, customizable platform to conduct tests to determine whether drugs or drug combinations would work in the clinical studies. Human cancers frequently display substantial intra-tumor heterogeneity. Therefore, we prepare tens of thousands of unpropagated tumor organoids with uniform size and shape that are pooled together to minimize well-to-well variability and maintain the heterogeneity of the tumor for ex vivo drug studies. We can perform complementary assays including our unique tumor cell killing assay utilizing high content confocal microscopy combined with proprietary algorithms and AI. This exclusive assay can be correlated with multiplex immunofluorescence staining, flow cytometry, multiplex cytokine analysis, RNA analysis and many more to objectively assess the impact of drug treatment on the tumor microenvironment.
Nilogen’s platforms can assess the efficacy of immuno-oncology agents and modulators including checkpoint inhibitors, antibody-based therapeutics, bi-specifics, oncolytic viruses, cell therapies and many others.